Drug Deal Disclosure Act
- Sponsor
- Rep. Chu, Judy [D-CA-28]
- Committees
- Budget Committee (primary)
- Last action
- Jul 15, 2026
Bottom line
This bill aims to increase transparency in federal drug pricing agreements by requiring public disclosure of confidential deals between the government and pharmaceutical manufacturers.
What it actually does
This bill mandates the Department of Health and Human Services (HHS) to publicly release all records, documents, and communications related to drug pricing agreements between federal entities and drug manufacturers entered into after January 20, 2025. These agreements include provisions related to most-favored-nation pricing, direct-to-consumer sales, import exemptions, US investment, special treatment in demonstration projects, Strategic National Stockpile contributions, or priority review vouchers. It specifically lists 17 such agreements for immediate disclosure and establishes an ongoing requirement for future agreements.
Proponents argue
Proponents argue that increased transparency in drug pricing agreements is crucial for understanding the true costs of prescription drugs, fostering competition, and ensuring accountability in government negotiations. They believe that public disclosure will empower consumers, policymakers, and researchers to better assess the value and fairness of these deals, potentially leading to lower drug costs and more equitable access.
Opponents contend
Opponents might argue that mandating the disclosure of proprietary pricing information could harm manufacturers' ability to negotiate competitive deals, potentially leading to less favorable terms for the government in the long run. They may also contend that certain information is legitimately confidential for business reasons and that forced disclosure could stifle innovation or discourage manufacturers from entering into agreements with the government.
The bill is concise and its core provisions are easily understandable, making it accessible for a quick but informed read.
Section 2(a)(1)
Mandated Public Disclosure of Drug Pricing Agreements
This section requires the Secretary of Health and Human Services to make publicly available, within 30 days of enactment, all records, documents, and communications related to drug pricing agreements between federal entities and drug manufacturers entered into on or after January 20, 2025. The information must be in a centralized, searchable, and downloadable format.
Supporters argue
Supporters argue this provision is essential for government transparency and accountability, allowing the public to scrutinize how federal agencies negotiate drug prices and what concessions are made.
Critics contend
Opponents might argue that such broad disclosure could compromise future negotiation leverage for the government and expose proprietary business information of manufacturers, potentially leading to less favorable deals or reduced participation in government programs.
Tradeoffs
The tension lies between the public's right to know and the potential for hindering future government negotiation effectiveness or impacting manufacturers' competitive strategies.
Section 2(a)(1)(A)-(G)
Specific Types of Agreement Provisions Requiring Disclosure
This section details the types of provisions within agreements that trigger the disclosure requirement. These include clauses related to most-favored-nation pricing (referencing foreign prices), direct-to-consumer sales, import duty exemptions, US investment commitments, special treatment in Medicare/Medicaid innovation models (like GLOBE or GUARD), contributions to the Strategic National Stockpile, or receipt of Commissioner's National Priority Review Vouchers.
Section 2(a)(2)
Explicitly Named Drug Manufacturer Agreements for Disclosure
The bill explicitly lists 17 specific agreements with major pharmaceutical companies (e.g., AbbVie, Amgen, AstraZeneca, Eli Lilly, Pfizer, Johnson & Johnson) that were publicly announced between September 2025 and April 2026. These agreements are specifically targeted for public disclosure under the Act.
Section 2(a)(3)
Ongoing Disclosure for Future and Modified Agreements
This section ensures that the disclosure requirements are not a one-time event. It mandates that any new agreements meeting the criteria in paragraph (1), or any modifications to the agreements listed in paragraph (2), entered into after the bill's enactment, must also be disclosed by the Secretary within 30 days of their ratification.
Section 2(b) and 2(c)
Rules for Redacting or Withholding Information
This section explicitly prohibits withholding, delaying, or redacting information based on reputational harm or political sensitivity. However, it permits withholding or redacting segregable portions that contain proprietary pricing information, pricing information legally prohibited from disclosure by foreign law or settlement, or information protected by other applicable law. Any such redaction must include a written justification published in the Federal Register and submitted to Congress, and the Secretary must disclose whether confidential pricing information was provided by each manufacturer.
Section 3
Congressional Reporting on Disclosed and Withheld Information
Within 15 days of completing the initial release of agreements, the Secretary must submit a report to specific Congressional committees. This report must list all documents and information released and withheld, along with a summary of all redactions and withholdings made, including their legal basis.
Section 4
Economic and Budgetary Analysis by CBO and GAO
Within 90 days of the initial release, the Director of the Congressional Budget Office (CBO) and the Comptroller General of the United States (GAO) are jointly required to publish a report. This report will analyze the economic and budgetary effects of all disclosed agreements, including direct cost savings for individuals, impacts on Medicare, Medicaid, and ACA health plans, and effects on drug price competition, anti-kickback statutes, and health plan formulary design.